Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostatic Diseases × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 7 Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Extensive Stage Lung Small Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

padeliporfin 2 talazoparib 1 sipuleucel-T 1 luprolide acetate gel depot 1 ixabepilone 1 enzalutamide 1 Therapeutics 1 Pluvicto 1 Paclitaxel 1 Nivolumab 1 Leuprolide 1 Ipilimumab 1 Imatinib Mesylate 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting

Prostatic Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡